Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

Phase 1

Terminated

Conditions: Purpura, Thrombocytopenic, Idiopathic

Interventions: Drug: BI 655064

First Posted Date: 2013-12-12

Last Posted Date: 2024-03-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 6

Registration Number: NCT02009761

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
New York Hospital, Cornell Medical Center, New York, New York, United States

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: tiotropium
Drug: placebo
Drug: olodaterol

First Posted Date: 2013-12-10

Last Posted Date: 2016-01-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 809

Registration Number: NCT02006732

Locations: 🇺🇸
1237.26.10613 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States
🇺🇸
1237.26.10606 Boehringer Ingelheim Investigational Site, Medford, Oregon, United States
🇦🇺
1237.26.61004 Boehringer Ingelheim Investigational Site, Concord, New South Wales, Australia

and more 75 locations

Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)

Phase 1

Terminated

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: decitabine iv
Drug: volasertib iv infusion

First Posted Date: 2013-12-06

Last Posted Date: 2019-01-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13

Registration Number: NCT02003573

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Washington School of Medicine, Saint Louis, Missouri, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes

Phase 3

Withdrawn

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Sitagliptin
Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2013-11-14

Last Posted Date: 2014-10-27

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT01984606

Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BI 207127
Drug: BI 207127 low fat
Drug: BI 207127 with Omeprazole
Drug: BI 207127 high fat

First Posted Date: 2013-11-14

Last Posted Date: 2016-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT01983566

Locations: 🇩🇪
1241.44.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany

Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

Phase 3

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Matching Placebo
Drug: Nintedanib

First Posted Date: 2013-11-08

Last Posted Date: 2018-04-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 113

Registration Number: NCT01979952

Locations: 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦
QEII Health Sciences Centre (Dalhousie University), Halifax, Nova Scotia, Canada
🇺🇸
Lowcountry Lung and Crit Care, Charleston, South Carolina, United States

and more 22 locations

Add-on to Micamlo BP Trial

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan + amlodipine
Drug: Placebo
Drug: hydrochlorothiazide

First Posted Date: 2013-11-03

Last Posted Date: 2016-11-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 309

Registration Number: NCT01975246

Locations: 🇯🇵
1348.1.022 Boehringer Ingelheim Investigational Site, Mihama-ku, Chiba, Chiba, Japan
🇯🇵
1348.1.004 Boehringer Ingelheim Investigational Site, Miyagino-ku, Sendai, Miyagi, Japan
🇯🇵
1348.1.025 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido, Japan

and more 27 locations

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Empagliflozin/Metformin XR, FDC
Drug: Empagliflozin/Metformin XR FDC
Drug: 25 mg Empagliflozin/1000 mg Metformin XR, FDC
Drug: 1 tablet Empagliflozin/3 tablets Metformin XR
Drug: 1 tablet Empagliflozin/2 tablets Metformin XR

First Posted Date: 2013-11-03

Last Posted Date: 2017-03-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT01975220

Locations: 🇺🇸
1276.13.1 Boehringer Ingelheim Investigational Site, Austin, Texas, United States

Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known

Phase 1

Completed

Conditions: Leukemia
Neoplasms

Interventions: Drug: volasertib

First Posted Date: 2013-10-29

Last Posted Date: 2018-07-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 22

Registration Number: NCT01971476

Locations: 🇧🇪
UNIV UZ Gent, Gent, Belgium
🇫🇷
INS Curie, Paris, France
🇨🇿
University Hospital Motol, Prague, Czechia

and more 2 locations

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo to BI 1060469
Drug: BI 1060469

First Posted Date: 2013-10-29

Last Posted Date: 2014-10-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68

Registration Number: NCT01971502

Locations: 🇩🇪
1333.1.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy